Workman P - Search Results

1

Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice.

Smith NF, Hayes A, Nutley BP, Raynaud FI, Workman P. Smith NF, et al. Among authors: workman p. Cancer Chemother Pharmacol. 2004 Dec;54(6):475-86. doi: 10.1007/s00280-004-0853-7. Epub 2004 Jul 29. Cancer Chemother Pharmacol. 2004. PMID: 15526201

2

Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).

Binger M, Workman P. Binger M, et al. Among authors: workman p. Cancer Chemother Pharmacol. 1991;29(1):37-47. doi: 10.1007/BF00686334. Cancer Chemother Pharmacol. 1991. PMID: 1742848

3

Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial.

Graham MA, Senan S, Robin H Jr, Eckhardt N, Lendrem D, Hincks J, Greenslade D, Rampling R, Kaye SB, von Roemeling R, Workman P. Graham MA, et al. Among authors: workman p. Cancer Chemother Pharmacol. 1997;40(1):1-10. doi: 10.1007/s002800050617. Cancer Chemother Pharmacol. 1997. PMID: 9137522 Clinical Trial.

4

Geldanamycin-induced cytotoxicity in human colon-cancer cell lines: evidence against the involvement of c-Src or DT-diaphorase.

Brunton VG, Steele G, Lewis AD, Workman P. Brunton VG, et al. Among authors: workman p. Cancer Chemother Pharmacol. 1998;41(5):417-22. doi: 10.1007/s002800050760. Cancer Chemother Pharmacol. 1998. PMID: 9523739

5

Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.

Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Hostein I, et al. Among authors: workman p. Cancer Res. 2001 May 15;61(10):4003-9. Cancer Res. 2001. PMID: 11358818

6

Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol.

Smith V, Raynaud F, Workman P, Kelland LR. Smith V, et al. Among authors: workman p. Mol Pharmacol. 2001 Nov;60(5):885-93. doi: 10.1124/mol.60.5.885. Mol Pharmacol. 2001. PMID: 11641415

7

HSP90 as a new therapeutic target for cancer therapy: the story unfolds.

Maloney A, Workman P. Maloney A, et al. Among authors: workman p. Expert Opin Biol Ther. 2002 Jan;2(1):3-24. doi: 10.1517/14712598.2.1.3. Expert Opin Biol Ther. 2002. PMID: 11772336 Review.

8

Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy.

Seddon BM, Maxwell RJ, Honess DJ, Grimshaw R, Raynaud F, Tozer GM, Workman P. Seddon BM, et al. Among authors: workman p. Clin Cancer Res. 2002 Jul;8(7):2323-35. Clin Cancer Res. 2002. PMID: 12114437

9

ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin.

Smith V, Hobbs S, Court W, Eccles S, Workman P, Kelland LR. Smith V, et al. Among authors: workman p. Anticancer Res. 2002 Jul-Aug;22(4):1993-9. Anticancer Res. 2002. PMID: 12174876

10

Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin.

Liu D, Hutchinson OC, Osman S, Price P, Workman P, Aboagye EO. Liu D, et al. Among authors: workman p. Br J Cancer. 2002 Sep 23;87(7):783-9. doi: 10.1038/sj.bjc.6600558. Br J Cancer. 2002. PMID: 12232764 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

605 results

Search Page

Filters